Beta-blockers and adverse effects: Dispelling the myths

Patient Care

Volumn 36, Issue 9, 2002, Pages 28-42

  Deedwania, Prakash C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347616227     PISSN: 0031305X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 1999;34:325-333.
2. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina: the TIBET Study Group. Eur Heart J. 1996;17:104-112.
3. Rehnqvist N, Hjemdahl P, Billing E, et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers: the APSIS study. Cardiologia. 1995;40(12 suppl 1):301.
4. Savonitto S, Ardissino D, Egstrup K, et al, for the IMAGE Study Group. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27:311-316.
5. von Arnim T for the TIBBS investigators. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol. 1995;25:231-238.
6. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83(suppl 2A):1A-38A.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
8. Hjalmarson Å, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000; 283:1295-1302.
9. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
10. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
11. The Beta-Blocker Evaluation Survival Trial Investigators. A trial of the beta-blocker bucindolol with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
12. Barron HV, Viskin S, Lundstrom RJ, et al. Beta-blocker dosages and mortality after myocardial infarction. Arch Intern Med. 1998;158:449-453.
13. Krumholz HM, Radford MJ, Wang Y, et al. Early beta-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med. 1999;131:648-654.
14. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
15. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115-121.
16. Wang TJ, Stafford RS. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med. 1998;158:1901-1916.
17. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [special article]. Arch Intern Med. 1997;157:2413-2446.
18. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 1999;33: 2092-2197.
19. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100:1016-1030.
20. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Circulation. 2001;104:2118-2150.
21. Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Card Failure. 1999;5:357-381.
22. Woolcock AJ, Anderson SD, Peat JK, et al. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis. 1991;143:1438-1443.
23. Gold MR, Dec GW, Cocca-Spofford D, et al. Esmolol and ventilatory function in cardiac patients with COPD. Chest. 1991;100:1215-1218.
24. Tafreshi MJ, Weinacker AB. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy. 1999;19:974-978.
25. Chen J, Marciniak TA, Radford MJ, et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients: results from the National Cooperative Cardiovascular Project J Am Coll Cardiol. 1999;34:1388-1394.
26. Giugliano D, Acapora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in noninsulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med. 1997;126:955-959.
27. MacDonald TM, Butler R, Newton RW, et al. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration. Diabet Med. 1998;15:282-289.
28. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
29. Zuanetti G, Latini R. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. J Diabetes Complications. 1997;11:131-136.
30. Deedwania PC, Giles TD, Ghali JK, et al. Safety and efficacy of treatment with metoprolol CR/XL in diabetic patients with heart failure (abstract). Circulation. 2000;102(suppl II):II-779.
31. Ried LD, McFarland BH, Johnson RE, et al. Beta-blockers and depression: the more the murkier? Ann Pharmacother. 1998;32:699-708.
32. Rathmann W, Haastert B, Roseman JM, et al. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol. 1999;52:1103-1109.
33. Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14:37-31.
34. Grimm RH Jr, Grandits GA, Prineas RJ, et al, for the TOMHS Research Group. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;290(1 pt 1):8-14.
35. Hiatt WR, Stoll S, Nies AS. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation. 1985;72:1226-1231.
36. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Int Med. 1991;151: 1769-1776.
37. Solomon SA, Ramsay LE, Yeo WW, et al. Beta-blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ. 1991;303:1100-1104.
38. Heintzen MP, Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J. 1994;15(suppl C):2-7.
39. Heidenreich PA, Lee TT, Massie B. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34.
40. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191.
41. Adams KF Jr, Baughman KL, Dec WG, et al. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches [special article]. Pharmacotherapy. 2000;20:495-522.
42. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens. 1993;15:967-978.
43. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.